Log In
Print this Print this

alefacept (Amevive) (ASP045)

Also known as: LFA-3/IgG, LFA3TIP (LFA-3/IgG)

  Manage Alerts
Collapse Summary General Information
Company Astellas Pharma Inc.
DescriptionRecombinant human LFA-3 fusion protein
Molecular Target CD58 (LFA-3)
Mechanism of ActionImmune modulation
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPhase II
Standard IndicationDiabetes
Indication DetailsTreat newly diagnosed Type I diabetes
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today